Therefore, the selective targeting of SIRT1 in cancer cells through tumor-specific delivery systems, context-dependent inhibitors, or exploitation of cancer-specific redox vulnerabilities should be prioritized to maximize therapeutic benefits while minimizing harm to normal tissues. Here, SIRT1 is linked to cancer.